Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mercator Moves To New Studies Following DANCE Success

Executive Summary

Results of DANCE, the first large-scale trial of Mercator’s Bullfrog micro-infusion catheter device, showed local dexamethasone-delivery with Bullfrog yields patient outcomes that compare favorably to that of drug-coated balloons in patients with peripheral artery disease. The company is pursuing more trials of Bullfrog in peripheral artery disease patients even though the device already has a CE mark and 510(k) clearance.

Advertisement

Related Content

Starts & Stops: New Trial Starts Led By Peripheral Vascular Interventions
Mercator Launches Trial Of Micro-Infusion Device For Lower-Leg Obstruction

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT103947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel